logo
Share SHARE
FONT-SIZE Plus   Neg

Blinkx Sees Annual Revenues Of $245 Mln - $247 Mln - Quick Facts

Blinkx Plc (BLNX.L), in its trading update for fiscal 2014, said it expects revenues to be in the range of $245 million - $247 million and adjusted EBITDA of $37 million - $39 million, in line with market view.

As announced earlier, the company would host a Capital Markets Day for Institutional Investors and Analysts in London today, which would include presentations by both the company and representatives from the online advertising ecosystem, followed by a panel discussion.

Today, blinkx also published a detailed response to a blog post dated January 28, 2014, that questioned its business model and practices. blinkx strongly refuted the assertions made in the blog at the time it was published.

"We are pleased with the performance of the business in FY2014, particularly with the successful integration of Rhythm in mobile video, despite the obvious distractions in the last quarter of the financial year," said Brian Mukherjee, Chief Executive Officer of blinkx.

The company expects to announce its fiscal 2014 results on May 6, 2014.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Database startup MongoDB has filed confidentially for initial public offering, aiming to go public before the end of the year, according to TechCrunch. The company, which develops enterprise-grade, open-source software including MongoDB NoSQL database, reportedly has submitted an S-1 filing in the past few weeks. Wal-Mart Stores Inc., the world's largest retailer, reported a decline in second-quarter profit with a significant charge. Adjusted earnings topped analysts' estimates with higher comparable sales. Looking ahead, for the third quarter, the company projects earnings in line or below market view. The company also issued earnings forecast for fiscal 2018. The development of Alzheimer's drugs has been marred by a high failure rate. A U.S. study, which analyzed how the Alzheimer's clinical trials fared during the period of 2002 to 2012, revealed a failure rate of 99.6% compared to a failure rate of 81% for cancer drugs.
comments powered by Disqus
Follow RTT